Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$69.36 +2.0%	$61.08	$52.50 ▼ $70.00	$1.51B	0.63	256,612 shs	279,136 shs
IDYA IDEAYA Biosciences	$16.35 +10.7%	$20.38	$13.73 ▼ $44.42	$1.43B	0.76	873,618 shs	2.15 million shs
RAPP Rapport Therapeutics	$9.96 +4.2%	$12.34	$6.43 ▼ $29.74	$363.50M	N/A	176,251 shs	160,510 shs
SDGR Schrödinger	$19.88 +5.5%	$22.98	$16.67 ▼ $29.15	$1.45B	1.62	763,185 shs	820,577 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+1.97%	+3.26%	+18.65%	+25.11%	+3.96%
IDYA IDEAYA Biosciences	+10.70%	-6.25%	-14.53%	-35.02%	-60.60%
RAPP Rapport Therapeutics	+4.18%	+2.68%	+39.30%	-45.84%	+995,999,900.00%
SDGR Schrödinger	+5.52%	-3.50%	-6.40%	-2.55%	-20.73%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.7962 of 5 stars	2.5	1.0	3.3	3.3	3.3	1.3
IDYA IDEAYA Biosciences	3.5081 of 5 stars	3.5	0.0	4.4	3.1	1.7	0.0
RAPP Rapport Therapeutics	1.7403 of 5 stars	3.5	0.0	0.0	2.3	1.7	0.6
SDGR Schrödinger	2.6218 of 5 stars	3.5	2.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$79.75	14.98% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$53.58	227.73% Upside
RAPP Rapport Therapeutics	3.00	Buy	$35.00	251.41% Upside
SDGR Schrödinger	3.00	Buy	$32.29	62.40% Upside

Current Analyst Ratings Breakdown

Latest RAPP, ANIP, SDGR, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/17/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$94.00 ➝ $94.00
3/14/2025	ANIP ANI Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
3/12/2025	ANIP ANI Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
3/5/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$84.00 ➝ $86.00
3/3/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$94.00 ➝ $94.00
2/27/2025	SDGR Schrödinger	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
2/14/2025	IDYA IDEAYA Biosciences	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
1/24/2025	SDGR Schrödinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $27.00
1/15/2025	IDYA IDEAYA Biosciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$61.00 ➝ $61.00
1/13/2025	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.46	$7.68 per share	9.03	$21.13 per share	3.28
IDYA IDEAYA Biosciences	$7M	204.46	N/A	N/A	$12.10 per share	1.35
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	$207.54M	7.00	$0.53 per share	37.42	$7.60 per share	2.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$18.78M	-$1.14	N/A	16.48	N/A	-1.28%	15.87%	6.88%	5/9/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.30	N/A	N/A	N/A	N/A	-26.74%	-25.54%	5/6/2025 (Estimated)
RAPP Rapport Therapeutics	-$34.79M	-$13.84	N/A	N/A	N/A	N/A	N/A	N/A	6/2/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.57	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	4/29/2025 (Estimated)

Latest RAPP, ANIP, SDGR, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	SDGR Schrödinger	-$0.81	N/A	N/A	N/A	$54.60 million	N/A
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million
2/13/2025	Q4 2024	IDYA IDEAYA Biosciences	-$0.67	-$1.49	-$0.82	-$1.49	$7.00 million	$7.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.52	2.74	1.97
IDYA IDEAYA Biosciences	N/A	14.97	22.93
RAPP Rapport Therapeutics	N/A	45.91	45.91
SDGR Schrödinger	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
IDYA IDEAYA Biosciences	98.29%
RAPP Rapport Therapeutics	N/A
SDGR Schrödinger	79.05%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	12.70%
IDYA IDEAYA Biosciences	3.50%
RAPP Rapport Therapeutics	N/A
SDGR Schrödinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.77 million	18.36 million	Optionable
IDYA IDEAYA Biosciences	80	87.54 million	84.47 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable

RAPP, ANIP, SDGR, and IDYA Headlines

Recent News About These Companies

Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans

March 27, 2025 | finance.yahoo.com

Schrödinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Buy" by Brokerages

March 27, 2025 | americanbankingnews.com

Schrödinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Buy" from Brokerages

March 27, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Trading Down 4.5% - What's Next?

March 26, 2025 | marketbeat.com

Schrödinger to Present Preclinical Data at AACR Annual Meeting

March 25, 2025 | finance.yahoo.com

Schrödinger, Inc. (NASDAQ:SDGR) Position Boosted by Amundi

March 21, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Shares Down 5.4% - What's Next?

March 19, 2025 | marketbeat.com

Tejara Capital Ltd Trims Stake in Schrödinger, Inc. (NASDAQ:SDGR)

March 19, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Boosts Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

March 18, 2025 | marketbeat.com

Bank of New York Mellon Corp Sells 27,211 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

March 16, 2025 | marketbeat.com

80,000 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Monaco Asset Management SAM

March 15, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Trading Up 11.3% - Should You Buy?

March 12, 2025 | marketbeat.com

Schrödinger beruft Bridget van Kralingen in den Vorstand

March 10, 2025 | de.investing.com

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 10, 2025 | finance.yahoo.com

SchrÃ¶dinger Expands Board of Directors with Appointment of Bridget van Kralingen

March 10, 2025 | businesswire.com

Insider Selling: Schrödinger, Inc. (NASDAQ:SDGR) CFO Sells 5,491 Shares of Stock

March 5, 2025 | marketbeat.com

Leerink Partnrs Estimates Schrödinger FY2029 Earnings

March 3, 2025 | marketbeat.com

SchrÃ¶dinger: Still Waiting On A Catalyst

March 2, 2025 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

March 1, 2025 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

March 1, 2025 | seekingalpha.com

Schrodinger price target lowered to $45 from $50 at Piper Sandler

February 27, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
Broaden Your ETF Exposure With These 3 Overlooked Funds
By Nathan Reiff | March 6, 2025
View Broaden Your ETF Exposure With These 3 Overlooked Funds

RAPP, ANIP, SDGR, and IDYA Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$69.36 +1.34 (+1.97%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$67.00 -2.36 (-3.40%)

As of 07:01 AM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

IDEAYA Biosciences NASDAQ:IDYA

$16.35 +1.58 (+10.70%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$13.73 -2.62 (-16.02%)

As of 06:29 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Rapport Therapeutics NASDAQ:RAPP

$9.96 +0.40 (+4.18%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$9.96 0.00 (0.00%)

As of 05:59 AM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Schrödinger NASDAQ:SDGR

$19.88 +1.04 (+5.52%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$18.82 -1.06 (-5.33%)

As of 07:18 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time